Trials / Terminated
TerminatedNCT00283634
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
A Randomized, Non-comparative, Multicenter, Open-Label, Phase 2 Study of Tarceva™ (Erlotinib) Alone and of Tarceva Plus VELCADE* (Bortezomib) for Injection in Patients With Relapsed or Refractory, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Tarceva, an orally available small molecule, has demonstrated potent activity in tumor models and humans. This randomized, open-label phase 2 study of Tarceva alone and of Tarceva plus VELCADE is designed primarily to determine the objective tumor response rates to these treatments in patients with Stage IIIB or Stage IV non-small cell lung cancer (NSCLC) that is refractory to or has relapsed after front-line chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | erlotinib and bortezomib |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2007-07-01
- Completion
- 2007-08-01
- First posted
- 2006-01-30
- Last updated
- 2011-02-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00283634. Inclusion in this directory is not an endorsement.